Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8572378 | 0.77 | HTT (0.32) | HTTKDM4EMAPK1HSD17B10 | |
| SCHEMBL4266121 | 0.76 | — | — | |
| SCHEMBL6961715 | 0.76 | IGF1R (0.31) | — | |
| SCHEMBL17411546 | 0.71 | SMN1; SMN2 (0.31) | KDM4EALDH1A1 | |
| SCHEMBL11593286 | 0.70 | KDM4E (0.33) | HTTKDM4EMAPK1ALDH1A1 | |
| SCHEMBL16446636 | 0.70 | GCGR (0.30) | KDM4E | |
| SCHEMBL1258640 | 0.69 | — | — | |
| SCHEMBL4273858 | 0.69 | TSHR (0.33) | — | |
| SCHEMBL1586206 | 0.67 | GAA (0.38) | KDM4EHSD17B10ALDH1A1KDM5B | |
| SCHEMBL21994461 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9801888-B2 | Pyrimidine compounds as mTOR and PI3K inhibitors | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2017-10-31 | — | — | US | disclosed |
| US-20160136176-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2016-05-19 | — | — | US | disclosed |
| US-9315491-B2 | Pyrimidine compounds as mTOR and PI3K inhibitors | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2016-04-19 | — | — | US | disclosed |
| US-20140178360-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | DCB-USA LLC (US) | 2014-06-26 | — | — | US | disclosed |
| US-20120288492-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | DCB-USA LLC (US) | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120288492-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | MTOR, PIK3CA, TYMS | HTT 3547/4885KDM4E 1949/4885MAPK1 261/4885 |
| US-20160136176-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | MTOR, PIK3CA, TYMS | HTT 3547/4885KDM4E 1949/4885MAPK1 261/4885 |
| US-20140178360-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | MTOR, PIK3CA, TYMS | HTT 3547/4885KDM4E 1949/4885MAPK1 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.